Engineered for high fluid absorption capacity, rapid hemostasis, and biocompatible tensile strength. Fully certified for global hospital tenders and distributor private labels.
Integrating pharmaceutical-grade gelatin purification, micro-porous foam extrusion, precision polymer braiding, laser needle swaging, and automated cleanroom blister sealing on one single site.
In modern surgical interventions—spanning neurosurgery, orthopedic reconstruction, dental extraction, abdominal trauma, and cardiovascular operations—rapid, reliable, and non-reactive intraoperative hemostasis is paramount. As a premier China Gelatin Sponge Factory & Supplier, our manufacturing infrastructure operates at the intersection of biopolymer physics, tissue engineering, and stringent medical device regulatory compliance.
Absorbable gelatin sponges are water-insoluble, porous, pliable matrixes prepared from purified pharmaceutical-grade gelatin derived from collagen. The critical engineering challenge lies in achieving a uniform spatial micro-porous structure. Our facility utilizes controlled physical foaming coupled with precise thermal cross-linking protocols to build a matrix featuring interconnected pores ranging between 40 µm and 120 µm.
This optimized pore distribution delivers two essential physiological mechanisms:
Unlike synthetic non-absorbable hemostats or non-controlled collagen sponges, high-grade absorbable gelatin sponges undergo enzymatic liquefaction without eliciting excessive foreign-body granulomatous tissue reactions. When implanted into soft tissue bleeding sites, the gelatin matrix undergoes complete enzymatic degradation by endogenous proteolytic enzymes (primarily collagenases and gelatinases).
Clinical absorption profiles demonstrate that complete bio-absorption occurs within 4 to 6 weeks (typically 28 to 45 days) without residual fibrous encapsulation or calcification. When applied to mucosal surfaces or open hemorrhaging cavities, the sponge liquefies within 2 to 5 days, making it the ideal solution for dental sockets, nasal packing, and anorectal procedures.
A primary failure mode in low-tier gelatin sponge manufacturing is the presence of unreacted aldehyde chemical cross-linking agents (such as glutaraldehyde), which induce localized inflammation, delayed healing, or cytotoxicity. Our factory implements advanced thermal-vacuum cross-linking technology (Dehydrothermal Treatment - DHT) combined with precise enzymatic stabilization, eliminating toxic residue risks completely.
All finished sponges and complementary bio-absorbable sutures undergo validated ethylene oxide (EO) or gamma irradiation sterilizing cycles, achieving a guaranteed Sterility Assurance Level (SAL) of 10⁻⁶ per ISO 11135 and ISO 11137 standards, with EO residual levels meticulously maintained below 1 ppm (far exceeding standard ISO 10993-7 requirements).
From custom OEM packaging configurations to comprehensive regulatory registration support, we empower medical device distributors, government health ministries, and brand partners globally.
We eliminate supply chain fragilities by handling raw gelatin extraction, polymer formulation, micro-foaming, freeze-drying, automated blister thermoforming, and EO sterilisation inside one ISO 13485:2016 verified plant in China.
Accelerate your local ministry approvals. We supply complete Technical Files, CE / EU MDR 2017/745 data, Free Sale Certificates (FSC), ISO 9001/13485 certificates, WHO-GMP compliance, Certificate of Analysis (CoA), and ISO 10993 biocompatibility test suites.
Full customization across sponge dimensions (standard 80x50x10mm, dental cubes 10x10x10mm, film formats), pore density, embedded thrombin/silver agents, foil pouches, GS1-compliant UDI barcoding, and multi-language IFU printings.
Every individual production lot undergoes physical pull-out testing, fluid absorption volumetric analysis, heavy metal screening, bacterial endotoxin testing (LAL test < 0.25 EU/ml), and sterility validation prior to batch release.
Standard catalog items dispatch in 2–3 weeks. For contract private-label programs, we maintain reserved raw material stocks and packaging plate archives, guaranteeing repeat order dispatches in under 15 business days.
Our experienced regulatory and international export desk works directly with national healthcare procurement agents, assisting in tender specifications, bid documentation, sample distribution, and localized logisitics.
The global bio-absorbable surgical devices market is undergoing a seismic paradigm shift. Hospitals, surgical centers, and procurement officers are moving away from traditional single-function hemostats toward multi-functional, bioactive matrixes that accelerate tissue regeneration while controlling cost-per-procedure.
Standard passive hemostatic agents are increasingly being augmented with active bioactive components. Future procurement trends indicate exponential demand for:
As laparoscopic, robotic, and endoscopic procedures replace open surgical approaches, traditional rigid hemostatic sponges face spatial delivery limitations. R&D in our China facility focuses on ultra-compressed shape-memory gelatin cylinders and plugs. These specialized sponges can be inserted through 5mm or 10mm trocar channels and rapidly expand upon contact with blood, conforming perfectly to deep cavity resection sites.
With the sunsetting of the EU Medical Device Directive (MDD) and the strict enforcement of EU MDR 2017/745, regulatory authorities require exhaustive clinical evaluation reports (CER), post-market clinical follow-up (PMCF), and precise raw material source traceability (PRSE - Transmissible Spongiform Encephalopathy compliance). Tier-1 healthcare buyers are rapidly divesting from uncertified suppliers unable to furnish full technical documentation.
Post-pandemic healthcare budget constraints are forcing health systems to eliminate intermediary trading markups. By establishing direct contracts with certified China factories, hospital networks achieve 30% to 50% cost reductions while acquiring higher-grade products backed by comprehensive quality assurances and custom OEM branding.
Objective benchmark comparing Bio-Absorbable Gelatin Sponges against alternative hemostats and wound closure matrixes.
| Absorbable Material Category | Primary Composition | Absorption Mechanism | Absorption Time | Hemostatic Efficacy | Tissue Reaction Profile | Relative Cost Efficiency |
|---|---|---|---|---|---|---|
| Gelatin Sponge (Our Flagship) | Purified Porcine/Bovine Gelatin | Enzymatic Liquefaction | 4 to 6 Weeks | High (Mechanical + Platelet Lysis) | Minimal / Non-Irritating | Excellent (High Yield / Low Cost) |
| Oxidized Regenerated Cellulose (ORC) | Alpha-Cellulose Derivative | Chemical Dissolution / Low pH | 1 to 2 Weeks | Moderate to High | Moderate (Low pH may cause stinging) | Moderate to High Cost |
| Collagen Fleece / Sheet | Native Fibrillar Collagen | Enzymatic Digestion | 6 to 8 Weeks | High (Direct Platelet Binding) | Low to Moderate | High Cost |
| Polyglactin 910 Suture (PGLA) | Copolymer (90% Glycolide, 10% L-lactide) | Hydrolytic Degradation | 56 to 70 Days | N/A (Structural Suture) | Extremely Low (Synthetic) | High Value / Long Shelf-Life |
| Polyglycolic Acid Suture (PGA) | 100% Homopolymer Polyglycolide | Hydrolytic Degradation | 60 to 90 Days | N/A (Structural Suture) | Extremely Low (Synthetic) | Cost-Effective High Tensile |
| Chromic Catgut Suture | Submucosal Sheep/Bovine Intestine | Phagocytosis / Enzymatic | Approx. 90 Days | N/A (Structural Suture) | Moderate (Foreign Protein Response) | Low Initial Cost |
Clear, definitive answers to the most common questions raised by medical device buyers, regulatory officers, and hospital supply chain managers.
Our competitive advantage stems from full vertical integration: we control raw material gelatin purification, thermal-vacuum cross-linking, precision freeze-drying, automated blister thermoforming, and cleanroom sterilisation under one ISO 13485:2016 accredited facility. We combine pharmaceutical-grade quality control with direct factory wholesale pricing, offering complete technical dossiers (CE, ISO, FSC, CoA) for seamless global registration.
The sponge operates through a dual physical-chemical mechanism. First, its uniform micro-porous matrix rapidly absorbs up to 45 times its weight in blood, creating a mechanical tamponade against bleeding vessels. Second, when blood enters the matrix, thrombocytes (platelets) break down upon contact with the sponge wall, releasing thromboplastin and initiating the natural clotting cascade to form a robust fibrin seal.
When implanted into soft tissue or surgical resections, the gelatin sponge is completely absorbed by endogenous proteolytic enzymes within 4 to 6 weeks (28 to 45 days) without leaving scar tissue or calcification. When applied to mucosal surfaces (such as nose, ears, or oral cavity), it liquefies within 2 to 5 days and can be easily washed or suctioned away.
We supply a turnkey regulatory registration dossier including ISO 13485:2016 Quality Management Certification, CE Mark / EU MDR Technical Files, WHO-GMP Compliance, Free Sale Certificates (FSC) legalised by the Ministry of Foreign Affairs, Certificates of Analysis (CoA) per lot, ISO 10993 Biocompatibility Validation reports, and validated Ethylene Oxide (EO) Sterility Assurance (SAL 10⁻⁶) documentation.
Yes. We offer extensive OEM/ODM customization. We manufacture standard surgical sheets (80x50x10mm), dental cubes (10x10x10mm), tamponade rolls for ENT/proctology, ultra-thin films, and compressed plugs. Packaging can be customized with your brand logo, custom foil printing, GS1-compliant UDI barcodes, and localized multi-language Instructions for Use (IFU).
For standard catalog items, our minimum order quantity starts at 1,000 boxes, with dispatch available within 10 to 15 business days. For customized OEM/private-label programs requiring custom packaging plates, initial batch lead times are 4 to 5 weeks from artwork approval; repeat orders dispatch in 2 to 3 weeks.
Sponges and bio-absorbable sutures are sealed in medical-grade aluminum-peel primary pouches inside a secondary peel-open envelope, preventing moisture and oxygen ingress. Sterilization is executed via validated ethylene oxide cycles. Accelerated and real-time aging studies per ASTM F1980 confirm a stable 5-year shelf-life when stored below 25°C in dry conditions.
While gelatin sponges provide rapid micro-vascular hemostasis across raw bleeding surfaces, PGA (Polyglycolic Acid) and PGLA (Polyglactin 910) absorbable sutures provide structural soft-tissue approximation. Both product lines share identical bio-absorption philosophies—providing predictable temporary support before cleanly degrading into naturally metabolic sub-components (glycolic and lactic acid), minimizing surgical site complications.
Maintained under strict international medical device standards to streamline import clearance for hospital tenders and regional distribution hubs.
Comprehensive Quality Management System auditing the entire design, raw material purification, cleanroom assembly, sterilization, and testing cycles for surgical absorbables.
Full Technical Documentation compliance including GSPR checklists, Risk Management (ISO 14971), Clinical Evaluation Summaries, and EUDAMED registration data.
Exhaustive third-party safety validation proving non-cytotoxicity, non-irritation, zero systemic toxicity, non-sensitization, and low pyrogen levels (LAL tested).
Elevate your hospital supply chain or medical device product line with certified bio-absorbable hemostats, PGA/PGLA sutures, and advanced wound dressings. Request product samples, factory technical dossiers, and competitive wholesale quotes today.
Inquire Now